86 related articles for article (PubMed ID: 26395347)
1. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
[TBL] [Abstract][Full Text] [Related]
2. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Yamamoto N; Kenmotsu H; Goto K; Takeda K; Kato T; Takeda M; Horinouchi H; Saito I; Sarashina A; Tanaka T; Morsli N; Nakagawa K
Cancer Chemother Pharmacol; 2018 Oct; 82(4):685-694. PubMed ID: 30073583
[TBL] [Abstract][Full Text] [Related]
3. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.
Mross K; Büchert M; Frost A; Medinger M; Stopfer P; Studeny M; Kaiser R
BMC Cancer; 2014 Jul; 14():510. PubMed ID: 25012508
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Lee CP; Taylor NJ; Attard G; Pacey S; Nathan PD; de Bono JS; Temple G; Bell S; Stefanic M; Stopfer P; Tang A; Koh DM; Collins DJ; d'Arcy J; Padhani AR; Leach MO; Judson IR; Rustin GJ
Oncologist; 2015 Apr; 20(4):368-9. PubMed ID: 25795637
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
Puzanov I; Lindsay CR; Goff L; Sosman J; Gilbert J; Berlin J; Poondru S; Simantov R; Gedrich R; Stephens A; Chan E; Evans TR
Clin Cancer Res; 2015 Feb; 21(4):701-11. PubMed ID: 25212606
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH; LoRusso P; Burris H; Gordon M; Bang YJ; Hellmann MD; Cervantes A; Ochoa de Olza M; Marabelle A; Hodi FS; Ahn MJ; Emens LA; Barlesi F; Hamid O; Calvo E; McDermott D; Soliman H; Rhee I; Lin R; Pourmohamad T; Suchomel J; Tsuhako A; Morrissey K; Mahrus S; Morley R; Pirzkall A; Davis SL
Clin Cancer Res; 2019 Jun; 25(11):3220-3228. PubMed ID: 30770348
[TBL] [Abstract][Full Text] [Related]
8. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD; Linossi C; Middleton M; Lord S; Harris A; Rodón J; Zitt C; Fiedler U; Dawson KM; Leupin N; Stumpp MT; Harstrick A; Azaro A; Fischer S; Omlin A
J Clin Oncol; 2021 Jan; 39(2):145-154. PubMed ID: 33301375
[TBL] [Abstract][Full Text] [Related]
10. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
Gjertsen BT; Schöffski P
Leukemia; 2015 Jan; 29(1):11-9. PubMed ID: 25027517
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.
Doi T; Fujiwara Y; Matsubara N; Tomomatsu J; Iwasa S; Tanaka A; Endo-Tsukude C; Nakagawa S; Takahashi S
Cancer Chemother Pharmacol; 2019 Aug; 84(2):393-404. PubMed ID: 31227862
[TBL] [Abstract][Full Text] [Related]
13. A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors.
Carducci MA; Wang D; Habermehl C; Bödding M; Rohdich F; Lignet F; Duecker K; Karpenko O; Pudelko L; Gimmi C; LoRusso P
Cancer Res Commun; 2023 Aug; 3(8):1638-1647. PubMed ID: 37637935
[TBL] [Abstract][Full Text] [Related]
14. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Dizon DS; Sill MW; Schilder JM; McGonigle KF; Rahman Z; Miller DS; Mutch DG; Leslie KK
Gynecol Oncol; 2014 Dec; 135(3):441-5. PubMed ID: 25312396
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with
Shitara K; Kim TM; Yokota T; Goto M; Satoh T; Ahn JH; Kim HS; Assadourian S; Gomez C; Harnois M; Hamauchi S; Kudo T; Doi T; Bang YJ
Oncotarget; 2017 Oct; 8(45):79546-79555. PubMed ID: 29108334
[TBL] [Abstract][Full Text] [Related]
16. Strategic and Statistical Considerations on the QT Assessment of Volasertib.
Wallenstein G; Walter B; Fritsch H; Taube T
Ther Innov Regul Sci; 2018 Jul; 52(4):416-422. PubMed ID: 29714574
[TBL] [Abstract][Full Text] [Related]
17. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.
Frost A; Mross K; Steinbild S; Hedbom S; Unger C; Kaiser R; Trommeshauser D; Munzert G
Curr Oncol; 2012 Feb; 19(1):e28-35. PubMed ID: 22328845
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Boulter AC; Maurer BJ; Pogue M; Kang MH; Cho H; Knight A; Reynolds CP; Quick D; Awasthi S; Gerber DE
Cancer Chemother Pharmacol; 2023 Aug; 92(2):97-105. PubMed ID: 37199745
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
Reck M; Mellemgaard A
Biologics; 2015; 9():47-56. PubMed ID: 26170616
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.
Kang YK; Ryu MH; Hong YS; Choi CM; Kim TW; Ryoo BY; Kim JE; Weis JR; Kingsford R; Park CH; Jang S; McGinn A; Werner TL; Sharma S
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38271925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
